Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG298

—

74ea883d-fcac-54e9-8275-2e41b43815c9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.483
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.458
  • KRAS_SIGNALING_DN+0.418
  • COAGULATION+0.325
  • MYOGENESIS+0.261
  • ESTROGEN_RESPONSE_LATE+0.257
  • APICAL_SURFACE+0.254
  • ESTROGEN_RESPONSE_EARLY+0.239
  • BILE_ACID_METABOLISM+0.224
  • HEDGEHOG_SIGNALING+0.224

Top 10 suppressed

  • MYC_TARGETS_V1-0.661
  • MYC_TARGETS_V2-0.590
  • OXIDATIVE_PHOSPHORYLATION-0.578
  • E2F_TARGETS-0.477
  • PI3K_AKT_MTOR_SIGNALING-0.475
  • DNA_REPAIR-0.467
  • G2M_CHECKPOINT-0.454
  • PROTEIN_SECRETION-0.422
  • MITOTIC_SPINDLE-0.419
  • UNFOLDED_PROTEIN_RESPONSE-0.413

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SRR1336292
brain-umap@2
GTEX—0.933
2SRR1330061
brain-umap@2
GTEX—0.926
3SRR1500428
brain-umap@2
GTEX—0.922
4SRR615096
brain-umap@2
GTEX—0.919
5SRR1312743
brain-umap@2
GTEX—0.917
6TCGA-ZF-A9R9-01A-11R-A38B-07
bladder-landscape@3
——0.914
7SRR1457221
brain-umap@2
GTEX—0.914
8TCGA-63-A5MG-01A-12R-A27Q-07
lung-landscapes@6
—cohortSQ10.914
9SRR934982
brain-umap@2
——0.913
10MNG325
mng-umap@100
——0.907

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.483Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.458Inavolisib— uncovered
KRAS_SIGNALING_DN0.418Remibrutinib— uncovered
COAGULATION0.325Binimetinib— uncovered
MYOGENESIS0.261Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.257Idelalisib— uncovered
APICAL_SURFACE0.254Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.239Inavolisib— uncovered
BILE_ACID_METABOLISM0.224Inavolisib— uncovered
HEDGEHOG_SIGNALING0.224Inavolisib— uncovered
PANCREAS_BETA_CELLS0.213Cobimetinib— uncovered
KRAS_SIGNALING_UP0.196Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.176Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.145Inavolisib— uncovered
HYPOXIA0.137Idelalisib— uncovered
IL2_STAT5_SIGNALING0.135Idelalisib— uncovered
XENOBIOTIC_METABOLISM0.123Inavolisib— uncovered
APICAL_JUNCTION0.101Inavolisib— uncovered
COMPLEMENT0.093Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.087Inavolisib— uncovered